Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2007-10-11
2011-10-25
Puttlitz, Karl J (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C562S465000
Reexamination Certificate
active
08044236
ABSTRACT:
A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1):wherein R1represents a C6-10aryl group; or a substituted C6-10aryl group, R2represents a C6-10aryl group; or a C6-10aryl group substituted with a group or groups selected from the group consisting of a halogen atom, nitro group, a C1-6alkyl group, a halogenated C1-6alkyl group, a C1-6alkoxy group, a halogenated C1-6alkoxy group, a phenyl group and carboxy group, X represents —CH2—, —CH2CH2—, —CH═CH— or —N(R3)—C(═O)—, Y represents carboxy group or a bioisostere of carboxy group, R3represents hydrogen atom, a C1-4alkyl group or a C7-12aralkyl group, m represents 0 or 1.
REFERENCES:
patent: 5324743 (1994-06-01), Dillard et al.
patent: 5462954 (1995-10-01), Baker et al.
patent: 5552441 (1996-09-01), Dillard et al.
patent: 5750530 (1998-05-01), Bryans et al.
patent: 5817684 (1998-10-01), Fleisch et al.
patent: 5891877 (1999-04-01), Brocchini et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 5914340 (1999-06-01), Fleisch et al.
patent: 5998454 (1999-12-01), Fleisch et al.
patent: 6589970 (2003-07-01), Commons et al.
patent: 6599925 (2003-07-01), Elokdah et al.
patent: 6800654 (2004-10-01), Mayers et al.
patent: 7056943 (2006-06-01), Elokdah et al.
patent: 7074817 (2006-07-01), Elokdah et al.
patent: 7074836 (2006-07-01), Kawada et al.
patent: 7101903 (2006-09-01), Elokdah et al.
patent: 7101915 (2006-09-01), Kawada et al.
patent: 7220783 (2007-05-01), Kawada et al.
patent: 7265148 (2007-09-01), Hu
patent: 7291639 (2007-11-01), Elokdah et al.
patent: 7491748 (2009-02-01), Tani et al.
patent: 7786161 (2010-08-01), Tani et al.
patent: 2004/0053962 (2004-03-01), Adrian
patent: 2004/0058965 (2004-03-01), Momose et al.
patent: 2005/0070584 (2005-03-01), Havran et al.
patent: 2005/0070585 (2005-03-01), Elokdah et al.
patent: 2005/0096377 (2005-05-01), Hu
patent: 2005/0119327 (2005-06-01), Hu
patent: 2005/0124664 (2005-06-01), Sartori et al.
patent: 2005/0124667 (2005-06-01), Sartori et al.
patent: 2005/0143384 (2005-06-01), Sartori et al.
patent: 2006/0020003 (2006-01-01), Commons et al.
patent: 2006/0173058 (2006-08-01), Brown et al.
patent: 2007/0207175 (2007-09-01), Clary et al.
patent: 2007/0213336 (2007-09-01), Clary et al.
patent: 2007/0276011 (2007-11-01), Muto et al.
patent: 1357115 (2003-10-01), None
patent: 1666469 (2006-06-01), None
patent: 2372740 (2002-09-01), None
patent: 2006-523196 (2006-10-01), None
patent: 95/21832 (1995-08-01), None
patent: 95/32190 (1995-11-01), None
patent: 96/36347 (1996-11-01), None
patent: 98/25600 (1998-06-01), None
patent: 98/25616 (1998-06-01), None
patent: 98/42334 (1998-10-01), None
patent: 98/42335 (1998-10-01), None
patent: 98/42336 (1998-10-01), None
patent: 98/42345 (1998-10-01), None
patent: 98/42346 (1998-10-01), None
patent: 98/42650 (1998-10-01), None
patent: 01/34135 (2001-05-01), None
patent: 01/34137 (2001-05-01), None
patent: 01/34197 (2001-05-01), None
patent: 01/34198 (2001-05-01), None
patent: 02/053547 (2002-07-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/000258 (2003-01-01), None
patent: 03/000649 (2003-01-01), None
patent: 03/000671 (2003-01-01), None
patent: 03/000684 (2003-01-01), None
patent: 2004/024939 (2004-03-01), None
patent: 2004/052856 (2004-06-01), None
patent: 2004/052893 (2004-06-01), None
patent: 2005/030192 (2005-04-01), None
patent: 2005/030204 (2005-04-01), None
patent: 2005/030702 (2005-04-01), None
patent: 2005/030715 (2005-04-01), None
patent: 2005/030716 (2005-04-01), None
patent: 2005/030756 (2005-04-01), None
Silverman, “Bioisosteres” in The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., 1992, pp. 19-23.
Franz et al., Synlett (2003), (4), 522-526.
Silverman, “Prodrugs” in The Organic Chemistry of Drug Design and Drug Action, ,Academic Press, Inc., 1992, pp. 353-355.
F.F. Paintner et al., “A New Convergent Approach to Biphenomycin Antibiotics”, Synlett, 2003, vol. 4, pp. 522-526.
J. Schneiderman et al., “Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries”, Proc. Natl. Acad. Sci. U.S.A., 1992, vol. 89, No. 15, pp. 6998-7002.
L.A. Erickson et al., “Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene”, Nature, 1990, vol. 346, pp. 74-76.
F. Samad et al., “Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice”, Molecular Medicine, 1996, vol. 2, No. 5, pp. 568-582.
K. Schaefer et al., “Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice”, FASAB J., 2001, vol. 15, No. 10, pp. 1840-1842.
H. Tsuchiya et al., “The Antibody to Plasminogen Activator Inhibitor-1 Suppresses Pulmonary Metastases of Human Fibrosarcoma in Athymic Mice”, Gen. Diagn. Pathol., 1995, vol. 141, No. 1, pp. 41-48.
K. Bajou et al., “Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization”, Nature Medicine, 1998, vol. 4, No. 8, pp. 923-928.
S. H. Cho et al., “Production of Plasminogen Activator Inhibitor-1 by Human Mast Cells and Its Possible Role in Asthma”, The Journal of Immunology, 2000, vol. 165, No. 6, pp. 3154-3161.
K. O. Chad et al., “PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model”, Biochemical and Biophysical Research Communications, 2002, vol. 294, No. 5, pp. 1155-1160.
P. Bjoerquist et al., “Identification of the Binding Site for a Low-Molecular-Weight Inhibitor of Plasminogen Activator Inhibitor Type 1 by Site-Directed Mutagenesis”, Biochemistry, 1998, vol. 37, No. 5, pp. 1227-1234.
H. Elokdah et al., “Tiplaxtinin, a Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical Characterization”, J. Med. Chem., 2004, vol. 47, No. 14, pp. 3491-3494.
C. A. Lipinski , “Bioisosterism in Drug Design”, Annual Reports in Medicinal Chemistry, 1986, vol. 21, pp. 283-291.
G. A. Patani et al., “Bioisosterism: A rational Approach to Drug Design”, Chem. Rev., 1996, vol. 96, pp. 3147-3176.
U.S. Appl. No. 11/870,741 (Yamaguchi et al.), filed Oct. 11, 2007, and entitled “N-Phenyloxamide Derivatives”.
Sawyer et al, “Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B4 receptor antagonist spatial positioning of the secondary acid group”, Bioorg. Med. Chem. Lett., 4,, 1994, pp. 2077-2082.
Jackson et al, “Comparison of antagonist and agonist binding to the leukotriene B4 receptor on intact human polymorphonuclear neutrophils (PMN)”, J. Pharm. Exp. Ther., 262, 1992, pp. 80-89.
Itai Akiko
Muto Susumu
Yamaguchi Youichi
Yanase Takeshi
Greenblum & Bernstein PLC
Institute of Medicinal Molecular Design Inc.
Puttlitz Karl J
LandOfFree
Carboxilic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxilic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxilic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297522